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Abstract  
Background and Purpose: Reduced ejection 
fraction (EF) ≤35% has been suggested as a criterion 
for anticoagulation in persons with heart failure in 
sinus rhythm, but the literature supporting EF as an 
independent stroke risk factor is conflicting. We here 
review the status of reduced EF as a stroke risk factor. 
Methods: We performed a Medline search 
combining terms for stroke and heart failure (HF) or 
cardiac left ventricular systolic dysfunction and 
reviewed evidence that reduced EF increases the risk 
of stroke. We also reviewed clinical and 
epidemiological HF studies that included data on 
stroke and EF.   
Results: Two of three longitudinal cohort studies 
found reduced EF (<50%) to be a stroke risk factor 
but did not find an inverse relationship between EF 
level and degree of stroke risk. Exploratory analyses 
of three clinical studies found an inverse relationship 
between EF level and degree of stroke risk but only in 
specific subgroups and vascular risk factors appeared 
to attenuate this relationship. Three analyses 
suggested an increased stroke risk with EF ≤20%.   
Conclusion: Reduced EF (<50%) probably 
increases stroke risk but this is not consistently 
demonstrated in all populations studied.   Reduced EF 
of any degree may be a surrogate for atherosclerotic 
cerebrovascular disease and in these patients 
traditional vascular risk factors may be more 
important for stroke risk than EF. There is no 
evidence to support EF ≤35% as a specific stroke risk 
factor. Research is needed to determine if very 
reduced EF (≤20%) is a specific stroke risk factor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 Ejection fraction (EF) is the percentage of cardiac 
left ventricular volume emptied in systole and is a 
reliable measure of left ventricular systolic 
dysfunction (LVSD). The prevalence of asymptomatic 
LVSD in the general population is about 3% to 6%1-3 
and about 37% of patients with heart failure (HF) in 
the United States have a reduced EF.4 Reduced EF is 
one of the principal indications for anticoagulation in 
dilated cardiomyopathy,5 and in 2006 the Heart 
Failure Society of America recommended that 
warfarin anticoagulation merits consideration in all 
patients with dilated cardiomyopathy and EF≤35%.6 
The most recent American College of Cardiology 
Foundation/American Heart Association Guidelines 
for the Management of Heart Failure7 however do not 
recommend anticoagulation in patients with chronic 
HF without atrial fibrillation and specifically do not 
mention a level of EF as an indication for 
anticoagulation. The data supporting a connection 
between reduced EF and an increased risk of stroke is 
therefore conflicting,8 and EF might not be the best 
criterion for selection of patients with LVSD for 
anticoagulation. Here we review the data supporting 
reduced EF as a risk factor for stroke. 
 
Methods 
We performed a Medline database search to 
identify potential studies. For cardiac dysfunction (left 
ventricular dysfunction) we used the exploded terms 
‘‘heart failure’’ ‘‘ventricular dysfunction, left,’’ and 
‘‘cardiac output, low’’ combined with the ‘‘or’’ 
operator. The stroke terms used were ‘‘brain 
infarction,’’ ‘‘brain ischaemia,’’ ‘‘stroke,’’ and 
‘‘intracranial embolism’’ combined with the ‘‘or’’ 
operator. Cardiac dysfunction terms were combined 
with the stroke terms using the “and” operator. The 
search was conducted during the week of July 22, 
2013. Articles were included regardless of year of 
publication. Additional articles were identified by 
hand-searching the reference lists of included articles 
identified by electronic search. Initial inclusion 
criteria were that the study contained a population 
with both EF data and reported the number (or 
percent) of persons with HF who experienced an 
ischemic stroke during follow-up, irrespective of heart 
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rhythm. Studies were excluded if the article did not 
separate ischemic strokes from hemorrhagic strokes, if 
>50% of the study population required artificial 
support with a ventricular assist device, or parenteral 
inotropic medications. Case reports, case series, 
reviews and non-original research articles were not 
included.  
Optimal study requirements to identify reduced 
EF as a stroke risk factor were: a) Stroke must be a 
pre-specified endpoint and EF measured in all 
participants, b) It should only include patients in sinus 
rhythm or include a multivariable analysis including 
atrial fibrillation as an independent variable. Desirable 
criteria include a) a multivariable analysis that 
includes prior stroke (or use only first ever stroke), 
and HF as independent variables, b) it should be a 
cohort study rather than an exploratory analysis of a 
clinical study, c) it should also look for increasing risk 
with decreasing levels of EF, d) it should include both 
ischemic and non-ischemic cardiomyopathy (which 
should be analysed separately).  Studies were 
reviewed against these criteria. We reviewed in detail 
those studies where the stroke or thromboembolism 
rate and EF were documented that were performed in 
patients in sinus rhythm or in whom a multivariable 
analysis including atrial fibrillation had been 
performed.  
 
Results 
The Medline search revealed 938 papers. Thirty-
five of these met initial study inclusion criteria. Hand 
searching of the references listed in these included 
articles and of the American College of Cardiology 
and American Heart Association meeting proceedings 
yielded an additional 20 papers that met initial 
inclusion criteria.  
We reviewed the remaining 55 papers in detail 
and selected those giving information relating EF to 
risk of stroke and thromboembolism. From these only 
159-23met one or more desirable criteria.(Table 1) No 
studies fulfilled the optimal or all of the desirable 
criteria. 
Studies were mainly either cohort studies, 
exploratory analyses of clinical studies or primarily 
echocardiographic studies. It was difficult to compare 
results between studies as there was no standard way 
of giving EF results: Most frequently results were 
expressed as the Relative Risk or Odds Ratio 10,13 of 
stroke or thromboembolism between normal and 
reduced EF (usually <50%) or EF strata. Frequency of 
patients with reduced EF with and without stroke were 
given in other papers,16 but others gave mean EF in 
the stroke and control groups23 or an odds ratio of an 
abnormal EF comparing stroke and control groups19. 
Individual EF results were only occasionally 
provided.  
We found only two cohort studies which fit 
desirable criteria9,11and one case control analysis of a 
subset from a cohort study.10 There were seven 
exploratory analyses of clinical studies that met 
desirable criteria.12-16,18,21 Two of three cohort studies 
found reduced EF (<50%) to be a risk factor for stroke 
but did not find an inverse relationship between EF 
level and degree of stroke risk.9,10 The three 
exploratory analyses found an inverse relationship 
between EF level and degree of stroke risk but only in 
specific subgroups and vascular risk factors appeared 
to attenuate this relationship. Three exploratory 
analyses suggested an increased stroke risk with EF 
≤20%.13-15 Of eight other studies showing data on EF 
and stroke, two found an association between EF and 
stroke16,23and six17-22did not. These papers varied in 
sample size and methodology and all were exploratory 
analyses.  
 
Discussion 
The largest cohort study to date that looks at the 
relationship of LVSD and stroke is the 
Cardiovascular Health Study.9 This study used Cox 
proportional hazard regression after adjustment for 
covariates to examine time to stroke in a community 
study of 5888 persons 65 years or older. All patients 
had EF estimation by two-dimensional 
echocardiography at baseline. They divided persons 
into three categories of left ventricular function 
(normal [EF ≥55%], borderline [45%-54%] and 
impaired [<45%] without HF and the same three 
categories of left ventricular function with HF. They 
found that the hazard ratio of stroke was 2.41 
(95%CI:1.3,4.5) (event rate 5.07 per 100 patient 
years) in persons with HF and borderline left 
ventricular systolic function and 1.91 (1.3,2.7) (event 
rate 4.52 per 100 patient years) in persons with HF 
and impaired left ventricular systolic function but 
hazard ratio for stroke was not significantly increased 
or of marginal significance in the other groups. Two 
negative aspects of this study are that it did not 
include prior stroke in the multivariable analysis and 
did not separate out persons with nonischaemic 
cardiomyopathy. Although the study found EF to be a 
risk factor for stroke in HF, the fact that there was no 
increasing hazard with decreasing EF would appear to 
go against the theory that stasis in a dilating ventricle 
increases thromboembolic risk. It suggests that 
decreased EF at any level is a non-specific risk factor 
for stroke. Reduced EF at any level might therefore be 
a surrogate for the presence of atherosclerotic 
cerebrovascular disease. The cut off for LVSD in this 
study was however very high at 45% and does not 
preclude a pro-thromboembolic effect at lower EF 
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levels. 
The Northern Manhattan study population was 
used for a case-control study in a subpopulation 
comparing 270 first stroke patients with 288 
controls.10 This study compared the frequency and 
severity of LVSD (mild: EF 41-50%, moderate: EF31-
40% and severe: ≤30%) in a multivariable analysis 
and found that the odds ratio of LVSD of any degree 
was 3.92 (95%CI 1.93,7.97) in patients with stroke 
compared to controls.(Table 2)  As in the 
Cardiovascular Health Study, there was no 
relationship between degree of EF reduction and 
stroke risk. All stroke risk factors including clinical 
HF were adjusted for, although the frequency of HF in 
the groups was not stated. These results reinforce the 
possibility that reduced EF at any level may be a non-
specific surrogate of cerebro-vascular disease. One 
interesting finding however was that in the subset 
(20%) of strokes that were cardioembolic, LVSD was 
more strongly related to stroke risk than in the other 
stroke subtypes. This suggests that decreased EF may 
impart a small pro-thromboembolic risk that is not 
apparent when all stroke subtypes are pooled.  
A further cohort study that included an analysis 
of EF was the Olmsted County study of ischemic 
stroke after HF.11 630 persons with incident HF were 
studied over a median of 4.3 years for the frequency 
of incident stroke. Baseline data comparing persons 
with (n=102) and without (n=528) subsequent stroke 
showed no significant difference in the frequency of 
EF<50% between the groups. In a very high stroke 
risk subgroup (19.8 per 100 patient years) within the 
first 30 days after HF diagnosis, the mean EF was 
>40%. A multivariable analysis of significant 
predictors of stroke >30 days after HF also showed 
that EF was not a significant risk factor for stroke. 
The drawbacks of this study are that EF was only 
available in about 50% of persons and there was no 
classification into ischemic and nonischaemic 
cardiomyopathy. Severity of HF by NYHA class was 
not given. This result does not support the 
Cardiovascular Health Study analysis linking EF to 
stroke risk in patients with HF. The finding that even 
in a very high stroke risk subgroup, the mean EF was 
only marginally decreased suggests that other risk 
factors for stroke are likely more important than 
reduced EF in stroke occurring in acute HF. 
The Survival and Ventricular Enlargement 
(SAVE)12 was the first exploratory analysis of a 
clinical trial of patients with LVSD to be published. 
SAVE was a study of 2,231 patients with EF ≤40% 
but without HF, enrolled a mean of 11 days after 
myocardial infarction. The patients were followed up 
for a mean of 42 months and had a low annual 
incidence of stroke of 1.5%. Patients with EF ≤28% 
had a relative risk of stroke of 1.86 compared with 
patients with EF of >35% (p=0.01). Age and 
decreased EF were significant risk factors for stroke in 
a multivariable analysis. Atrial fibrillation was not a 
risk factor for stroke but up to 31% of patients were 
on anticoagulation and this significantly reduced 
stroke risk. Neither hypertension nor diabetes was a 
risk factor for stroke. The SAVE study found that EF 
(especially EF ≤28%) was the most important 
independent predictor of stroke in patients after 
MI.(Figure 1) In addition, the risk of stroke increased 
by 1.18 times for every absolute decrease of 5% in the 
EF. Men made up 83% of the study sample. A 
concern about this study is that prior stroke was not 
included in the multivariable analysis and since prior 
stroke is a known strong risk factor for stroke,11 its 
exclusion might have allowed LVSD to become a 
significant risk factor. This criticism could also be 
levelled at the Cardiovascular Health Study results for 
stroke discussed above and at the Sudden Cardiac 
Death in Heart Failure (SCD-Heft) trial outlined 
below.  
The Studies of Left Ventricular Dysfunction 
(SOLVD) thromboembolism analysis13 included 6,378 
patients with EF≤35% in sinus rhythm, half of whom 
had symptomatic HF.  All thromboembolic events: 
strokes, pulmonary and peripheral emboli were 
included together in the main analysis. Separate 
analyses were performed for men and women since a 
significant interaction between EF and gender was 
found (p=0.04). In an average follow up time of 40 
months there were 1.82 events per 100 participant 
years of follow up in men and 2.42 events per 100 
participant years in women. The SOLVD trial found 
that EF was independently related to thromboembolic 
risk, in women but not in men (fig 3). Multivariable 
analysis of the relative risk for a thromboembolic 
event per 10% decrease in EF was 1.53 
(95%CI:1.06,2.20) in women and 1.08 
(95%CI:0.89,2.20) in men. In SOLVD, multivariable 
risk factors for thromboembolism were dominated by 
prior stroke, diabetes and age in men, and EF did not 
reach significance. In women diabetes was the 
strongest, and only vascular, risk factor and EF was 
also a risk factor for thromboembolism.  Sex 
differences in pathogenesis of thromboembolism are 
also suggested by the finding that in women but not in 
men, the relative risk of thromboembolic events was 
2.17 [95%CI:1.10-4.30] times the risk with EF 11-
20% than with EF ≥30%. Since a high percentage of 
endpoints were pulmonary emboli, a repeat 
multivariable analysis was performed excluding these 
cases to look at risk factors for stroke alone. 
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Table 1: Details of 15 studies examined. EF ejection fraction;  HF: heart failure; HR: hazard ratio, RR: Relative 
risk; OR: Odds ratio; MVA: multivariable analysis. 
Reference   % with HF  
(NYHA 
class) 
Stroke rate 
(no of 
strokes/total 
no of 
patients) 
EF cut-offs How EF 
compared 
Atrial 
Fibrillation 
% excluded/ 
MVA 
EF Risk of 
stroke? And 
level 
Prior stroke 
included in 
MVA 
9 Gottdiener 
CHS 
4.9% 12.5-50.7 per 
1000 pt. yrs. 
5532 total 
patients 
Borderline 
<55%, 
impaired 
45% 
HR for 
stroke in 
normal vs 
low EF 
groups 
2% HR:Borderline:  
+HF:2.41; 
Impaired: -HF: 
1.27; +HF: 1.91 
No 
10 Hays 
NOMASS 
Not stated 277 strokes 
288 controls 
mild 41-
50%; mod 
31-40%; 
severe ≤30 
OR for mild, 
mod or 
severe ↓EF 
in strokes vs 
controls  
10% of 
strokes 
OR: mild: 4.0; 
mod/severe 3.9; 
All ↓EF: 3.9 
Not relevant  
11 Witt 
Olmsted 
County Study 
100%  102/630 <50% (EF 
missing in 
50% of 
strokes) 
RR of stroke 
with↓EF  
47% of 
strokes 
(adjusted for 
in MVA) 
P 0.014 (but EF 
lower in non-
stroke) 
Yes  
12 Loh  
SAVE 
0% “overt 
HF” 
103/2231 All pts : 
<40%: 3 
gps:<28% ; 
29-35%; 
>35% 
RR of stroke 
in MVA 
16% of 
strokes 
(adjusted in 
MVA) 
RR: 1.18: 18% 
increase in stroke 
for 5% ↓EF 
No 
13 Dries 
SOLVD 
38% 226/6378 All pts: 
≤35%: 4 
gps:≥30%; 
21-30%; 
11-20%; 
≤10% 
RR of 
thrombo-
embolic 
events 
excluded RR: 1.53 per 
10% ↓EF 
Yes 
14 Freuden-
berger  
SCD-Heft 
(All pts 
NYHA II or 
III) 
56/2114 All pts: 
≤35%: 
HR for 
thrombo-
embolic 
events 
excluded HR 0.82 per 5% 
↑EF 
Yes 
15 Falk 
PROMISE 
(All pts 
NYHA III or 
IV) 
22/1088 All pts: 
≤35%: 1 
subgp  
% with 
stroke 
EF≤20% vs 
EF>20% 
Not stated Warfarin reduced 
stroke in 
EF≤20%: p<0.05  
No MVA 
16 Fox  
ARIC 
0.04% 98/1792 50% % with low 
EF: stroke vs 
no-stroke 
Not stated P<0.0001 No MVA 
17 Siachos 100% 
(NYHA III 
or IV) 
34/168 20% EF in stroke 
vs no-stroke 
Excluded P=0.82 excluded 
18 Mujib 
DIG 
100% 222/7788 <35% OR for 
stroke in 
↓EF  
excluded P=0.85 No 
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Table 1: Details of 15 studies examined. EF ejection fraction;  HF: heart failure; HR: hazard ratio, RR: Relative 
risk; OR: Odds ratio; MVA: multivariable analysis (cont.). 
Reference   % with HF  
(NYHA 
class) 
Stroke rate 
(no of 
strokes/total 
no of 
patients) 
EF cut-offs How EF 
compared 
Atrial 
Fibrillation 
% excluded/ 
MVA 
EF Risk of 
stroke? And 
level 
Prior stroke 
included in 
MVA 
19 Mahajan Not stated 73 strokes 73 
controls 
All pts: 
≤35%: 
EF in stroke 
gp vs EF in 
controls 
excluded P0.38 No MVA 
 
20 Komori 
100% (70% 
NYHA III or 
IV) 
10/111 43%-45% EF in stroke 
gp vs EF in 
no-stroke 
10% of 
strokes 
P 0.7 No  
21 Szummer 
VALIANT 
26% 81/5573 43%-49% EF in stroke 
gp vs EF in 
no-stroke 
16% of 
strokes 
0.081 Yes 
22 Deleu Not stated 72 strokes 79 
controls 
37%-50% EF in stroke 
gp vs EF in 
no-stroke 
Not stated Not significant No 
23 Kozdag  Mean 
NYHA class 
III 
18 strokes 28 
no stroke 
29%-34% EF in stroke 
gp vs EF in 
no-stroke 
Not stated P 0.03. Not 
significant in 
MVA 
No  
 
 
Table 2: LV function in stroke patients and control subjects in the Northern Manhattan Study10.  
Normal LVEF >50%, mild LV dysfunction 41-50%, moderate 31-40% and severe <30%. ±Adjusted for age, gender, 
AF, diabetes mellitus, hypertension, hypercholesterolemia, current smoking, CAD, HF and LV mass index.  
  
 Stroke 
patients, n (%) 
Control 
subjects, n (%) 
Unadjusted  
Odds Ratio 
(CI) 
±Adjusted Odds 
Ratio (CI) 
Normal LV 
function 
205 (75.9) 274 (95.1)   
LV dysfunction 
Any degree 
65 (24.1) 14 (4.9) 6.21 (3.39-
11.37) 
3.92 (1.93-7.97) 
Mild LV 
dysfunction 
29 (10.7) 7 (2.4) 5.54 (2.38-
12.89) 
3.96 (1.56-10.0) 
Moderate/Severe 
LV dysfunction 
36 (13.3) 7 (2.4) 6.87 (3.00-
15.75) 
3.88 (1.45-10.39) 
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Figure 1: Cumulative rate of stroke in the SAVE trial according to left ventricular EF 12
 
 
In these results, in women, EF was no longer a 
significant risk factor, and prior stroke and smoking 
became significant. This suggests that the 
pathogenesis of thromboembolism is different from 
that of stroke, and that EF is less important as a risk 
factor for stroke than for thromboembolism. The 
reason for this is likely that the risk of a clinical 
ischemic event in the brain is increased by pre-
existing vascular disease risk factors, which may not 
be the case for other locations of embolism. SOLVD 
also appears to show that the pathogenesis of 
thromboembolism is more likely to be related to 
reduced EF in women than in men, possibly because 
in men multiple strong vascular risk factors override 
any effect of reduced EF and make it undetectable.    
A third trial analysis that showed an inverse 
relationship between thromboembolism risk and EF 
was that of the SCD-Heft Trial.14 2114 patients in 
sinus rhythm enrolled in this implanted cardiac 
defibrillator study were followed over a median 45.5 
months for stroke and peripheral or pulmonary 
embolism. Hypertension (Hazard Ratio [HR] 1.86 
[95%CI:1.10,3.13]) and EF (HR 0.82[0.69,0.97] for 
every 5% decrease) were the only risk factors for 
thromboembolism. Two concerns about these results 
however are that the multivariable analysis did not 
include prior stroke, even though up to 7% of patients 
had prior stroke.  
Secondly, stroke was not analysed separately 
from other thromboembolic events and when transient 
ischemic attack was included as an endpoint, EF was 
no longer a significant predictor of thromboembolism. 
The authors commented that ischemic stroke in LVSD 
may be related to severity of cerebral arterial disease 
rather than thromboembolism alone, echoing what 
several of the studies above appear to show.  
The fact that these three trials have shown an inverse 
relationship between EF and thromboembolism/stroke 
risk does support a specific effect of severe LVSD on 
thromboembolism risk, independent of reduced EF of 
any level being a surrogate marker of cerebrovascular 
disease. The three trials that showed this relationship, 
all studied EF below 28%,12-14 whereas those failing to 
show this relationship9-11had cutoffs for LVSD that 
were higher. SOLVD data show that the rate of 
thromboembolism increases significantly with an EF 
of 11-20% in women13 (Table 3) and the SCD-Heft 
data also shows an increase in stroke with an EF of 
20%.14 (Figure 2) This is similar to an earlier finding 
that in severe HF in patients with an EF of 20% the 
stroke rate was increased and was reduced with 
warfarin.15 These three analyses suggest that the left 
ventricle may only become a significant source of 
thromboembolism with very low EFs around 20%, 
and this may be one factor why the other studies 
above failed to show an inverse relationship between 
thromboembolism and stroke.
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Table 3: Incidence and relative risk of thromboembolism according to gender and EF quartile from the SOLVD trial. 
CI = confidence interval. Adapted from Dries et al. (1997).13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Proportion of patients with thromboembolic events in three strata of baseline Efs. SCD
-Heft Study.14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LVEF  Incidence  Relative Risk (95% CI)  
Men, n=5457  
≤30%  1.70  1.00  
21-30%  1.83  1.08 (0.83-1.41)  
11-20%  2.01  1.21 (0.86-1.70)  
≤10%  1.96  1.21 (0.30-4.92)  
Women, n=921  
≤30%  1.78  1.00  
21-30%  2.41  1.35 (0.74-2.47)  
11-20%  3.80  2.17 (1.10-4.30)  
≤10%  4.20  2.43 (0.32-18.26)  
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